Another study found that the incidence of irAEs was higher in patients with NSCLC who received PD-1/PD-L1 inhibitors plus chemotherapy compared to those who received PD-1/PD-L1 inhibitors alone [18]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.